A double-blind, placebo-controlled pivotal study of Safinamide to evaluate the efficacy of safinamide in Parkinson's disease patients with levodopa induced dyskinesia (PD LID)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 21 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Sep 2021 According to a Newron Pharmaceuticals media release, the company is currently working on finalizing the design of the study with international clinical experts and regulatory authorities and intends to initiate the study in Q1 2022
19 Mar 2021 New trial record
15 Mar 2021 According to a Newron Pharmaceuticals media release, company signed an agreement regarding this study. Under the agreement with its partner Zambon, Newron will sponsor the study and be responsible for its development and execution, as well as leading on all related regulatory interactions. Newron and Zambon will evenly share the cost of the study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com